Optimal Duration of antiplatelet Therapy after Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events
Not Applicable
Recruiting
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0002908
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Age 19 and more
On dual or triple antiplatelet therapy and between 12months and 14months from Bioresorbable Vascular Scaffold implantation
No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding
Exclusion Criteria
Contraindication to antiplatelet therapy
Need to continue clopidogrel due to stroke, peripheral disease, significant carotid disease or recent acute coronary syndrome
Major bleeding history or bleeding diathesis
Life expentancy less than 1year due to non-cardiac disease
Pregnancy
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite event of death, myocardial infarction, or stroke
- Secondary Outcome Measures
Name Time Method Stroke;Myocardial infarction;Target Lesion Revascularization;Stent thrombosis;Bleeding;Target Vessel Revascularization